{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:55:03Z","timestamp":1792644903964,"version":"4.5.0"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Neuroblastoma (NB) is an immunologically \u201ccold\u201d tumor with poor or no inflamed substrates as most of solid pediatric tumors (SPT). Consistent data indicate that NB tumor microenvironment (TME) is dominated by myeloid cells, with little (but variable) T cell infiltration. The obstacles to lymphocyte infiltration and to their anti-tumor activity are due to different tumor immune evasion strategies, including loss of HLA Class I molecules, high expression of immune checkpoint molecular ligands leading to exhaustion of T effector (and NK) cells, induction of T regulatory, myeloid and stromal cells and secretion of immunosuppressive mediators. In odds with adult solid tumors, NB displays weak immunogenicity caused by intrinsic low mutational burden and scant expression of neoepitopes in the context of MHC-class I antigens which, in turn, are particularly poorly expressed on NB cells, thus inducing low anti-tumor T cell responses. In addition, NB is generated from embryonal cells and is the result of transcriptional abnormalities and not of the accumulation of genetic mutations over time, thus further explaining the low immunogenicity. The poor expression of immunogenic molecules on tumor cells is associated with the high production of immunosuppressive factors which further downregulate lymphocyte infiltration and activity, thus explaining the limited efficacy of new drugs in NB, as immune checkpoint inhibitors. This review is focused on examining the role of T effector and regulatory cells infiltrating TME of NB, taking into account their repertoire, phenotype, function, plasticity and, importantly, predictive value for defining novel targets for therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1544137","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:02:05Z","timestamp":1740726125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Enrico","family":"Maggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Landolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Munari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Azzarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01990","article-title":"Positive & Negative roles of innate effector cells in controlling cancer progression","volume":"9","author":"Stolk","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.156","article-title":"Implications of the tumor immune microenvironment for staging and therapeutics","volume":"31","author":"Taube","year":"2018","journal-title":"Mod Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","article-title":"Tumor microenvironment: Sanctuary of the devil","volume":"368","author":"Hui","year":"2015","journal-title":"Cancer Lett"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1299303","article-title":"Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma","volume":"6","author":"Jacquelot","year":"2017","journal-title":"Oncoimmunology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16073","DOI":"10.1038\/ncomms16073","article-title":"Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8(+) T cells","volume":"8","author":"Enamorado","year":"2017","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.cell.2017.08.024","article-title":"Organism-level analysis of vaccination reveals networks of protection across tissues","volume":"171","author":"Kadoki","year":"2017","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680973","article-title":"Impact of PD-L1 and PD-1 expression on the prognostic significance of CD8(+) tumor-infiltrating lymphocytes in non-small cell lung cancer","volume":"12","author":"Munari","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0692","article-title":"Immunotherapy of pediatric solid tumors: treatments at a crossroads, with an emphasis on antibodies","volume":"8","author":"Casey","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01640","article-title":"The state of cellular adoptive immunotherapy for neuroblastoma and other pediatric solid tumors","volume":"8","author":"Le","year":"2017","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Grobner","year":"2018","journal-title":"Nature"},{"key":"B15","article-title":"Neuroblastoma\u2013biology confronts nosology","volume":"110","author":"Triche","year":"1986","journal-title":"Arch Pathol Lab Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.07.002","article-title":"Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research","volume":"21","author":"Ora","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.sempedsurg.2011.10.009","article-title":"Neuroblastoma","volume":"21","author":"Davidoff","year":"2012","journal-title":"Semin Pediatr Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2007","article-title":"Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience\u2013a pediatric oncology group study","volume":"16","author":"Katzenstein","year":"1998","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0603-z","article-title":"Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma","volume":"54","author":"Wolfl","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.11.064","article-title":"Mechanisms of immune evasion of human neuroblastoma","volume":"228","author":"Raffaghello","year":"2005","journal-title":"Cancer Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.014","article-title":"The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology","volume":"144","author":"Wienke","year":"2021","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccell.2023.12.008","article-title":"Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy","volume":"42","author":"Wienke","year":"2024","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100657","DOI":"10.1016\/j.xcrm.2022.100657","article-title":"The immune cell atlas of human neuroblastoma","volume":"3","author":"Verhoeven","year":"2022","journal-title":"Cell Rep Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e23618","DOI":"10.4161\/onci.23618","article-title":"The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes","volume":"2","author":"Carlson","year":"2013","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1019981","DOI":"10.1080\/2162402X.2015.1019981","article-title":"Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma","volume":"4","author":"Mina","year":"2015","journal-title":"Oncoimmunology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3109\/15513815.2012.754527","article-title":"The immune environment of paediatric solid Malignancies: evidence from an immunohistochemical study of clinical cases","volume":"32","author":"Apps","year":"2013","journal-title":"Fetal Pediatr Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v123.19","article-title":"Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues","volume":"123","author":"Majzner","year":"2017","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1249553","article-title":"CD4(+)CD25(hi)CD127(-) Treg and CD4(+)CD45R0(+)CD49b(+)LAG3(+) Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma","volume":"5","author":"Morandi","year":"2016","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/jcp.v236.1","article-title":"Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma","volume":"236","author":"Jin","year":"2021","journal-title":"J Cell Physiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031462","article-title":"Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2","volume":"199","author":"Metelitsa","year":"2004","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050267","article-title":"Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma","volume":"42","author":"Facchetti","year":"1996","journal-title":"Cancer Immunol Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3314","article-title":"Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma","volume":"24","author":"Coughlin","year":"2006","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41591-020-0844-1","article-title":"A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors","volume":"26","author":"Slyper","year":"2020","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1186\/s12885-018-4910-8","article-title":"Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients","volume":"18","author":"Camisaschi","year":"2018","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01473","article-title":"MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an in silico immunological analysis of TARGET database","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e8017","DOI":"10.7717\/peerj.8017","article-title":"Cellular components in tumor microenvironment of neuroblastoma and the prognostic value","volume":"7","author":"Zhong","year":"2019","journal-title":"PeerJ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26498","article-title":"Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments","volume":"131","author":"Soldati","year":"2012","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173337","article-title":"Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature","volume":"9","author":"Mei","year":"2024","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1320626","article-title":"Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression","volume":"6","author":"Layer","year":"2017","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.6.3114","article-title":"Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells","volume":"167","author":"Metelitsa","year":"2001","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.169","article-title":"Immunocombination therapy for high-risk neuroblastoma","volume":"4","author":"Kroesen","year":"2012","journal-title":"Immunotherapy"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.09.012","article-title":"Immunology and immunotherapy of neuroblastoma","volume":"21","author":"Seeger","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2601","article-title":"PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma","volume":"23","author":"Melaiu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0599","article-title":"Clinically relevant cytotoxic immune cell signatures and clonal expansion of T-cell receptors in high-risk MYCN-not-amplified human neuroblastoma","volume":"24","author":"Wei","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200107000-00006","article-title":"Major histocompatibility complex-restricted lysis of neuroblastoma cells by autologous cytotoxic T lymphocytes","volume":"24","author":"Sarkar","year":"2001","journal-title":"J Immunother"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216373","article-title":"Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function","volume":"14","author":"Olle Hurtado","year":"2019","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v6i34","article-title":"Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma","volume":"6","author":"Spel","year":"2015","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804577","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0412-2","article-title":"Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma","volume":"57","author":"De Geer","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcancer.2017.03.001","article-title":"Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation","volume":"43","author":"Huber","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26018","article-title":"Low frequency of programmed death ligand 1 expression in pediatric cancers","volume":"3","author":"Aoki","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jss.2023.03.042","article-title":"CD69 on tumor-infiltrating cells correlates with neuroblastoma suppression by simultaneous PD-1 and PD-L1 blockade","volume":"289","author":"Inoue","year":"2023","journal-title":"J Surg Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.15.8099","article-title":"Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer","volume":"94","author":"Kwon","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","article-title":"Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule","volume":"53","author":"Gregorio","year":"2008","journal-title":"Histopathology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405025101","article-title":"Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis","volume":"101","author":"Castriconi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02589-6","article-title":"CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment","volume":"69","author":"Xin","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00383-017-4185-1","article-title":"Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with Malignant solid tumors","volume":"34","author":"Hishiki","year":"2018","journal-title":"Pediatr Surg Int"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00873","article-title":"Enhancing neuroblastoma immunotherapies by engaging iNKT and NK cells","volume":"11","author":"McNerney","year":"2020","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"347867","DOI":"10.1155\/2015\/347867","article-title":"Expression of FOXP3, CD14, and ARG1 in neuroblastoma tumor tissue from high-risk patients predicts event-free and overall survival","volume":"2015","author":"Stigliani","year":"2015","journal-title":"BioMed Res Int"},{"key":"B62","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ijc.29465","article-title":"Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis","volume":"137","author":"HaDuong","year":"2015","journal-title":"Int J Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1316439","article-title":"MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma","volume":"6","author":"Brandetti","year":"2017","journal-title":"Oncoimmunology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/cas.2019.110.issue-3","article-title":"Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation","volume":"110","author":"Harada","year":"2019","journal-title":"Cancer Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.174","article-title":"Human FOXP3 and cancer","volume":"29","author":"Martin","year":"2010","journal-title":"Oncogene"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3216","article-title":"The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature","volume":"18","author":"deLeeuw","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-170","article-title":"Distinct signatures of the immune responses in low risk versus high risk neuroblastoma","volume":"170","author":"Gowda","year":"2011","journal-title":"J Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2014.886002","article-title":"Circulating T-regulatory cells in neuroblastoma: a pilot prospective study","volume":"31","author":"Tilak","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2011.10.002","article-title":"Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions","volume":"23","author":"Yamaguchi","year":"2011","journal-title":"Semin Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34262","article-title":"Depletion of Foxp3+ regulatory T cells but not the absence of CD19+IL-10+ regulatory B cells hinders tumor growth in a para-orthotopic neuroblastoma mouse model","volume":"151","author":"Weissenborn","year":"2022","journal-title":"Int J Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016683","article-title":"Identification of hub genes and their correlation with infiltration of immune cells in MYCN positive neuroblastoma based on WGCNA and LASSO algorithm","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/path.2016.240.issue-2","article-title":"Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development","volume":"240","author":"Hashimoto","year":"2016","journal-title":"J Pathol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.12.004","article-title":"Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions","volume":"32","author":"Hegazy","year":"2010","journal-title":"Immunity"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112825","article-title":"How the immune system responds to allergy immunotherapy","volume":"10","author":"Veneziani","year":"2022","journal-title":"Biomedicines"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.07.015","article-title":"Modulating Treg stability to improve cancer immunotherapy","volume":"9","author":"Kang","year":"2023","journal-title":"Trends Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.v101.2","article-title":"Regulatory T-cell stability and functional plasticity in health and disease","volume":"101","author":"Malviya","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3899","article-title":"Neuroblastoma is composed of two super-enhancer-associated differentiation states","volume":"49","author":"van Groningen","year":"2017","journal-title":"Nat Genet"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3921","article-title":"Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries","volume":"49","author":"Boeva","year":"2017","journal-title":"Nat Genet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41597-020-0458-y","article-title":"Epigenomic profiling of neuroblastoma cell lines","volume":"7","author":"Upton","year":"2020","journal-title":"Sci Data"},{"key":"B81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discovery"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1268645","article-title":"Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity","volume":"14","author":"D\u2019Amico","year":"2023","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"111455","DOI":"10.1016\/j.celrep.2022.111455","article-title":"Single-cell profiling of peripheral neuroblastic tumors identifies an aggressive transitional state that bridges an adrenergic-mesenchymal trajectory","volume":"41","author":"Yuan","year":"2022","journal-title":"Cell Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00427-5","article-title":"Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes","volume":"3","author":"Sengupta","year":"2022","journal-title":"Nat Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0214","article-title":"Characterizing relationships between T-cell inflammation and outcomes in patients with high-risk neuroblastoma according to mesenchymal and adrenergic signatures","volume":"4","author":"Kaufman","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102358119","article-title":"Epigenetic state determines inflammatory sensing in neuroblastoma","volume":"119","author":"Wolpaw","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B87","doi-asserted-by":"publisher","first-page":"PO.18.00413","DOI":"10.1200\/PO.18.00413","article-title":"Mesenchymal neuroblastoma cells are undetected by current mRNA marker panels: the development of a specific neuroblastoma mesenchymal minimal residual disease panel","volume":"3","author":"van Wezel","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2007-0454","article-title":"Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling","volume":"26","author":"Liotta","year":"2008","journal-title":"Stem Cells"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41467-023-38239-5","article-title":"Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma","volume":"14","author":"Thirant","year":"2023","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001313","article-title":"Identification of neuroblastoma cell lines with uncommon TAZ(+)\/mesenchymal stromal cell phenotype with strong suppressive activity on natural killer cells","volume":"9","author":"Canzonetta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382931","article-title":"Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells","volume":"15","author":"Di Matteo","year":"2024","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1989.tb08497.x","article-title":"Suppression of MHC class I gene expression by N-myc through enhancer inactivation","volume":"8","author":"Lenardo","year":"1989","journal-title":"EMBO J"},{"key":"B93","article-title":"Neuroblastoma: a disease requiring a multitude of imaging studies","volume":"45","author":"Kushner","year":"2004","journal-title":"J Nucl Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30751","article-title":"Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma","volume":"117","author":"Song","year":"2007","journal-title":"J Clin Invest"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/cancers12071739","article-title":"Expression patterns of immune genes reveal heterogeneous subtypes of high-risk neuroblastoma","volume":"12","author":"Liu","year":"2020","journal-title":"Cancers"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631546","article-title":"Prognostic signature of immune genes and immune-related lncRNAs in neuroblastoma: A study based on GEO and TARGET datasets","volume":"11","author":"Zhong","year":"2021","journal-title":"Front Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41467-019-14134-w","article-title":"Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms","volume":"11","author":"Pelon","year":"2020","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004807","article-title":"Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma","volume":"10","author":"Costa","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.771210","article-title":"Targeting the CCL2\/CCR2 axis in cancer immunotherapy: one stone, three birds","volume":"12","author":"Fei","year":"2021","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1166860","article-title":"Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2586","article-title":"Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells","volume":"77","author":"Borriello","year":"2017","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3358","article-title":"Anti-CD105 antibody eliminates tumor microenvironment cells and enhances anti-GD2 antibody immunotherapy of neuroblastoma with activated natural killer cells","volume":"25","author":"Wu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1186\/s12885-018-5082-2","article-title":"Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells","volume":"18","author":"Pelizzo","year":"2018","journal-title":"BMC Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers15010019","article-title":"Neuroblastoma tumor-associated mesenchymal stromal cells regulate the cytolytic functions of NK cells","volume":"15","author":"Di Matteo","year":"2022","journal-title":"Cancers"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3390\/life12111714","article-title":"Exosomes in neuroblastoma biology, diagnosis, and treatment","volume":"12","author":"Jahangiri","year":"2022","journal-title":"Life (Basel)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01146","article-title":"Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13045-021-01193-0","article-title":"Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma","volume":"14","author":"Tumino","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803014","article-title":"Polymorphonuclear myeloid-derived suppressor cells are abundant in peripheral blood of cancer patients and suppress natural killer cell anti-tumor activity","volume":"12","author":"Tumino","year":"2021","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"107363","DOI":"10.1016\/j.phrs.2024.107363","article-title":"Homodimerization of CB(2) cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling","volume":"208","author":"Navarro","year":"2024","journal-title":"Pharmacol Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2146860","DOI":"10.1080\/2162402X.2022.2146860","article-title":"Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-beta\/IL-6 pathway in neuroblastoma","volume":"11","author":"Louault","year":"2022","journal-title":"Oncoimmunology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ijms17091566","article-title":"The role of galectin-1 in cancer progression, and synthetic multivalent systems for the study of galectin-1","volume":"17","author":"Cousin","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41598-017-01279-1","article-title":"Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy","volume":"7","author":"Van Woensel","year":"2017","journal-title":"Sci Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1131378","article-title":"Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma","volume":"5","author":"Buchel","year":"2016","journal-title":"Oncoimmunology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1159\/000064028","article-title":"Production of macrophage migration inhibitory factor by human and murine neuroblastoma","volume":"23","author":"Bin","year":"2002","journal-title":"Tumour Biol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/378736a0","article-title":"Apoptosis of T cells mediated by galectin-1","volume":"378","author":"Perillo","year":"1995","journal-title":"Nature"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2006.01.006","article-title":"Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation","volume":"33","author":"Yan","year":"2006","journal-title":"Cytokine"},{"key":"B120","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/brainsci9100284","article-title":"Overexpression of macrophage migration inhibitory factor and its homologue D-dopachrome tautomerase as negative prognostic factor in neuroblastoma","volume":"9","author":"Cavalli","year":"2019","journal-title":"Brain Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37869","article-title":"Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J Clin Invest"},{"key":"B122","article-title":"Human tumor gangliosides inhibit murine immune responses","volume":"55","author":"Li","year":"1995","journal-title":"vivo. Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijc.2910430103","article-title":"Immunosuppressive activity of human neuroblastoma tumor gangliosides","volume":"43","author":"Floutsis","year":"1989","journal-title":"Int J Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3443","article-title":"Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity","volume":"75","author":"Mussai","year":"2015","journal-title":"Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04316","article-title":"Downregulation and\/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma","volume":"6","author":"Raffaghello","year":"2004","journal-title":"Neoplasia"},{"key":"B126","doi-asserted-by":"publisher","first-page":"283ra55","DOI":"10.1126\/scitranslmed.aaa2327","article-title":"Clinical impact of the NKp30\/B7-H6 axis in high-risk neuroblastoma patients","volume":"7","author":"Semeraro","year":"2015","journal-title":"Sci Transl Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4588","article-title":"Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release","volume":"67","author":"Morandi","year":"2007","journal-title":"Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"7946021","DOI":"10.1155\/2018\/7946021","article-title":"Secretory high-mobility group box 1 protein affects regulatory T cell differentiation in neuroblastoma microenvironment","volume":"2018","author":"Vanichapol","year":"2018","journal-title":"In Vitro. J Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001502","article-title":"GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNgamma overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape","volume":"9","author":"Caforio","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"106359","DOI":"10.1016\/j.isci.2023.106359","article-title":"Integrative multi-omics approaches to explore immune cell functions: Challenges and opportunities","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/s41467-022-30549-4","article-title":"The use of single-cell multi-omics in immuno-oncology","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-024-03728-w","article-title":"Implementation of multi-omics in diagnosis of pediatric rare diseases","author":"Ali","year":"2024","journal-title":"Pediatr Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B134","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discovery"},{"key":"B136","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"B137","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci Transl Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg7962","article-title":"Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo","volume":"16","author":"Diez-Alonso","year":"2024","journal-title":"Sci Transl Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B143","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.esmoop.2020.100046","article-title":"Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy","volume":"6","author":"Fuca","year":"2021","journal-title":"ESMO Open"},{"key":"B144","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological Malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2529","article-title":"The genetic landscape of high-risk neuroblastoma","volume":"45","author":"Pugh","year":"2013","journal-title":"Nat Genet"},{"key":"B147","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: a double-edged sword in cancer treatment","volume":"71","author":"Behranvand","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30355-8","article-title":"Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial","volume":"18","author":"Mody","year":"2017","journal-title":"Lancet Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0379","article-title":"A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent\/refractory neuroblastoma","volume":"23","author":"Federico","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: A report from the children\u2019s oncology group","volume":"38","author":"Mody","year":"2020","journal-title":"J Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1452","article-title":"A phase II trial of hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma","volume":"25","author":"Furman","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134132","article-title":"Orally bioavailable CDK9\/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma","volume":"130","author":"Poon","year":"2020","journal-title":"J Clin Invest"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1114","article-title":"Dual ALK and CDK4\/6 inhibition demonstrates synergy against neuroblastoma","volume":"23","author":"Wood","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B157","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-020-00171-8","article-title":"Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma","volume":"2","author":"Roeschert","year":"2021","journal-title":"Nat Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1356","article-title":"Immunotherapy of neuroblastoma: facts and hopes","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/BF01741792","article-title":"Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype","volume":"34","author":"Rivoltini","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220310","article-title":"Gamma\/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors","volume":"22","author":"Nanno","year":"1992","journal-title":"Eur J Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.632779","article-title":"Isoalantolactone increases the sensitivity of prostate cancer cells to cisplatin treatment by inducing oxidative stress","volume":"9","author":"Huang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02493","article-title":"Engineering CAR-T cells for improved function against solid tumors","volume":"9","author":"Morgan","year":"2018","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"B167","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"B168","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544137\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:02:11Z","timestamp":1740726131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544137\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":168,"alternative-id":["10.3389\/fimmu.2025.1544137"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1544137","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"1544137"}}